Group 1 - The company Xingqi Eye Medicine has received drug registration approval from the National Medical Products Administration for its 0.02% and 0.04% atropine sulfate eye drops on January 4, 2026 [2] - The company is currently coordinating its market promotion plan and is in the production preparation stage [2]

Group 1 - The company has received drug registration approval for its 0.02% and 0.04% atropine eye drops from the National Medical Products Administration on January 4, 2026 [2] - The company is currently coordinating its market promotion plan and is in the production preparation stage [2]

Core Viewpoint - The approval of 0.02% and 0.04% atropine sulfate eye drops by the National Medical Products Administration represents a significant breakthrough for the company, enhancing treatment options for myopia progression in children aged 6 to 12 years [1][4]. Company Summary - The newly approved products are aimed at delaying myopia progression in children with spherical degrees between -1.00D and -4.00D, with astigmatism and anisometropia not exceeding 1.50D [1]. - Following the approval, the company's stock price increased by 4.82% on January 5, reaching 73.68 CNY per share, and continued to rise to 74.2 CNY on January 6, with a total market capitalization of 18.285 billion CNY [1]. - The company’s 0.01% atropine sulfate eye drops have already established a stable market share and clinical recognition, paving the way for the new products to capture market opportunities [2]. Industry Summary - The market for myopia prevention and control is expanding, with a reported overall myopia rate of 51.9% among children and adolescents in China as of 2022 [6]. - The approval of low-concentration atropine eye drops is supported by the 2024 edition of the "Myopia Prevention and Control Guidelines," which recognizes these drops as effective in delaying myopia progression [4]. - The competitive landscape is intensifying, with several pharmaceutical companies entering the market, including Heng Rui Medicine and Zhaoke Ophthalmology, which have submitted applications for similar products [7][8]. - The estimated market size for atropine in myopia management ranges from approximately 5.29 billion CNY to 20.39 billion CNY, indicating significant growth potential [7].

Core Viewpoint - The approval of 0.02% and 0.04% atropine eye drops marks a significant milestone in the prevention and control of myopia among children and adolescents in China, transitioning from a "single concentration" approach to a "stair-step concentration" model, enabling personalized and precise interventions [1][3][6] Group 1: Market Context - The overall myopia rate among children and adolescents in China is 51.9%, showing a slight decrease from 2021, but the situation remains severe with a high prevalence of early-onset and severe cases [2] - The introduction of varying concentrations of atropine eye drops responds to the clinical need for tailored solutions, particularly for high-risk children who may not benefit from a single concentration [2][7] Group 2: Product Development - The newly approved eye drops underwent rigorous randomized double-blind clinical trials, demonstrating their effectiveness and safety in delaying the progression of myopia in children [3][4] - The clinical study involved 800 participants across 28 centers, with a treatment duration of 2 years and a 1-year observation period post-treatment, confirming the efficacy of the new concentrations compared to a placebo [4] Group 3: Company Profile - Shenyang Xingqi Eye Medicine Co., Ltd. has been a pioneer in the research and development of atropine eye drops for myopia control, initiating its low-concentration atropine project in 2014 and collaborating with Singapore's National Eye Centre in 2016 [5] - The company has developed a comprehensive management drug covering different stages of myopia progression, showcasing its innovative capabilities in the ophthalmic pharmaceutical field [5] Group 4: Health Policy Alignment - The approval of these new concentrations aligns with the "Healthy China 2030" initiative, enhancing the drug treatment system for myopia prevention and providing robust support for achieving national health goals [6]